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Preformulation is an important step in the rational formulation of an active pharmaceutical ingredient (API). Micromeritics
properties: bulk density (BD) and tapped density (TD), compressibility index (Carr’s index), Hauser’s ratio (H), and sieve analysis
were performed in order to determine the best excipients to be used in the formulation development of omeprazole magnesium
enteric coated tablets. Results show that omeprazole magnesium has fair flow and compressibility properties (BD 0.4 g/mL, TD
0.485 g/mL, Carr’s index 17.5%, Hauser’s ratio 1.2, and sieve analysis time 5 minutes). There were no significant drug excipient
interactions except change in colour in all three conditions in the mixture of omeprazole and aerosil 200. Moisture content loss
on drying in all three conditions was not constant and the changes were attributed to surrounding environment during the test
time. Changes in the absorption spectra were noted in the mixture of omeprazole and water aerosil only in the visible region of
350–2500 nm. Omeprazole magnesium alone and with all excipients showed no significant changes in omeprazole concentration
for a 30-day period. Omeprazole magnesium formulation complies with USP standards with regards to the fineness, flowability,
and compressibility of which other excipients can be used in the formulation.
1. Introduction
Preformulation is the first step in the rational formulation
of an active pharmaceutical ingredient (API). It is an inves-
tigation of the physicochemical properties of the drug sub-
stance, alone and in combination with excipients [1]. Ome-
prazole, 5-methoxy-2(((4-methoxy-3,5-dimethyl-2-pyridin-
yl)methyl)sulfinyl)-1H-benzimidazole, is a potent inhibitor
of gastric acid secretion [2]; see Figure 1. It is among pro-
ton pump inhibitors (PPI) and shows powerful inhibitory
action against secretion of gastric juice and is used in treat-
ment of duodenal and gastric ulcers, erosive or ulcerative gas-
troesophageal reflux disease (GERD), and pathological hy-
persecretory conditions (Zollinger-Ellison) [2]. However,
omeprazole is susceptible to degradation/transformation in
acid reacting and neural media [3].
The in vitro degradation of omeprazole is catalyzed by
acidic environment and is stabilized in mixtures in alkaline
environment. Moisture and organic solvents also affect the
stability of omeprazole [4]. From omeprazole stability studies
data, it is obvious that an oral dosage formmust be protected
from contact with gastric juice in order to reach the small
intestine without degradation [1, 3–5].
Therefore exposure of omeprazole magnesium to the acid
condition of the stomach would lead to significant degrada-
tion of the drug and hence reduce bioavailability [6]. A
pharmaceutical dosage form with properties of protecting
omeprazole from contact with gastric acid must be devel-
oped, which is core tablet. The core must be enteric coated.
The core developedmust be alkaline in nature asmost of avai-
lable acidic coating materials such as phthalate-phthalic acid
esters or acrylate-acrylic acid copolymers (KILLOCOATE
MAE) will not favor stability of omeprazole [6, 7].
The aim of the present work was to perform preformu-
lation studies to inform development of omeprazole enteric
coated tablets for the purpose of determining the physical
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Figure 1: Structure of omeprazole.
chemical characteristics of omeprazole with possible interac-
tions with excipients.
2. Experimental
2.1. Equipment. Bulk density apparatus (IPAFlowmatics Pvt.,
Ltd., Bangalore, India), graduated cylinder (Fisher Scientific,
Germany), sieve analyzer (Endecott’s, Germany), glass bottles
(Fisher Scientific, Germany), stability chambers (Thermolab
Scientific Pvt., Ltd., Vasai, India), hot oven, near infrared
absorption spectroscopy (Advanced System Development
(ASD) Inc., NIR Systems, Boulder, Colorado, USA), HPLC
(Shimadzu, Japan), and fast moisture tester (Guoming,
China).
2.2. Materials. Omeprazole magnesium (Metrochem API
Private Limited, Hyderabad, India), sodium lauryl sulphate
(LOBAChemie Pvt. Ltd., Mumbai, India), lactose (OXFORD
Laboratories, Mumbai, India), Avicel PH 102 (Shandong
Liaocheng Ehuamedicine Co. Ltd., Shandong, China), maize
starch (OXFORDLaboratories,Mumbai, India), water aerosil
200 (Shandong Liaocheng Ehua medicine Co. Ltd., Shan-
dong, China), and magnesium stearate (Huzhou Zhanwang
Pharmaceutical Co. Ltd., Huzhou, China) were used. Other
reagents and solvents were procured commercially in local
market and were of pharmaceutical and analytical grade.
2.3. Procedures
2.3.1. Preformulation Studies
(1) Micromeritics Properties of API
(A) Bulk Density and Tapped Density. Both bulk density (BD)
and tapped density (TD) including compressibility index
were determined as prescribed in USP30NF35. The com-
pressibility index of the powder blend was determined by
Carr’s index.This can be used to predict flow properties based
on density measurement [6, 8]. The formula for Carr’s index
is shown below:
Carr’s index (%) =




(B) Hausner’s Ratio (H).This expresses the flow properties of
the powder and is measured by the ratio of tapped density
(TD) to bulk density (BD) [6, 8]. It is calculated from the
following equation:




























Figure 2: Sieve analysis cumulative weight of retained granules (%)
versus sieve size (𝜇m) curve.
Powder blend was evaluated for bulk density and tapped
density, compressibility index, and Hausner’s ratio as des-
cribed above. Additionally the assay was performed as per
monograph for determination of omeprazole magnesium
USP30NF35 [3].
(C) Sieve Analysis. The main aim of sieve analysis was to
determine the distribution of different size of drug particles
present [8]. A series of sieves was arranged in the order of
their deceasing pore diameter, that is, sieves numbers 0, 45,
90, 125, 180, 250, 355, 500, 710, and 1000. About 100 grams
of drug was weighed accurately and transferred to sieve 1000
which was kept on the top. The sieves were shaken for about
5 minutes. Then the drug retained on each of the sieves
was taken, weighted separately, and expressed in terms of
percentage. The limit is expected as in Table 1 [8]. The results
of sieve analysis are shown in Figure 2.
2.3.2. Drug Excipients Compatibility Studies. Drug excipient
compatibility studies were carried out by mixing drug with
potential excipient. The ratio of formulation excipients to
active substances was maintained at a ratio of 1 : 1. The
mixtures were filled in closed vials and placed in stability
chambers in the conditions as prescribed in US Pharma-
copeia 30NF25 [4]. Table 2 depicts the composition of core
tablets.
The preparation of samples for compatibility studies
considered the amount of active ingredients and excipients
as described in US Pharmacopeia 30NF25.The sample of the
mixtures was mixed with API and excipients as prescribed
in the study proposal. The set of samples were mixed well to
ensure homogenicity.
The possible interactions between omeprazole magne-
sium and excipients were evaluated by examining the pure
drug and drug excipient powder mixtures which were stored
under conditions as depicted inTable 1 for a period of 90 days.
The following parameters were assessed: appearance and
colour, moisture content, near infrared (NIR), and assay by
high performance liquid chromatography (HPLC) for omep-
razole and related substances.The frequency of sampling was
days 0, 3, 7, 30, 60, and 90.
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Table 1: Conditions to which samples were subjected.
Container Temperature Humidity Bottle status
Set A Room temperature (30 ± 2∘C) Controlled Plastic bottle closed
Set B Climatic chamber (40 ± 2∘C) Relative humidity 75% Plastic bottle opened
Set C Oven (50∘C) Not controlled Plastic bottle closed
Table 2: Composition of core tablets.
Ingredient Specifications Qty/tablet (mg) Qty/batch (g) Reasons for inclusion
(1) Omeprazole magnesium USP 20mg 80 g Active
(2) SLS (SDS) USP 2mg 8 g Lubricant
(3) Tablettose (lactose) USP 76mg 304 g Binder
(4) Avicel ph 101 USP 60mg 240 g Disintegrant
(5) Starch USP 40mg 160 g Diluent
(6) Water aerosil 200 USP 0.6mg 2.4 g Glidant
(7) Magnesium stearate USP 1.4mg 5.6 g Lubricant
200mg 800 g
The powder was scanned using NIR spectrophotometer.
The procedure was started by cleaning the working area and
assured that there was no dust. The device was switched on
(Muglight and the laboratory spec.). The device was calib-
rated and the base line for omeprazole powder and mixture
for day zero were recorded. The samples of the powder were
filled in the vials and sample count was set to average of 30-
sample count.
3. Results and Discussion
3.1. Micromeritics Properties. Results of micromeritics stud-
ies as presented in Table 3 showed that Hauser’s ratio was 1.2
and Carr’s index was 17.5% which indicates that omeprazole
magnesium has fair compressibility and flowability proper-
ties, respectively. Therefore it is important to improve flow
and compressibility property [4].
The results of sieve analysis show that omeprazole mag-
nesium has a 𝐷
50
value of 100 𝜇m which is within the range
of 90 to 125 𝜇m and it indicates that omeprazole magnesium
powder is moderately fine [4].
The results of Hauser ratio and compressibility index
obtained have shown that flowability of omeprazole magne-
sium was fair. This will help in selection and determination
of the optimal excipients and amount of the excipients to be
used. That is, it is recommended that about 0.07% of mag-
nesium stearate should be used to improve the flowability of
the powder during formulation.
The flowability and compressibility of omeprazole mag-
nesium powder indicate that the powder is suitable for both
direct compression and wet granulation method depending
on the other excipients used with their respective amounts
that could be used instead.
Physical observation during drug excipient compatibility
studies and physical observation indicates no significant
drug-excipient interaction was observed except for the mix-
ture of omeprazole and aerosil 200 which show change in
Reference day 0 Room temperature day 90
Climatic chamber day 90 Oven day 90
















Figure 3: Absorption NIR spectra for omeprazole magnesium
alone.
colour in all three conditions.Therefore from the study it was
concluded that the omeprazole magnesium and other excip-
ients were compatible with each other as results are depicted
in Table 4.
3.2. Moisture Content. The values of moisture content
obtained by using loss on drying method indicate that the
amount of moisture present in all the samples subjected to
all three different storage conditions was not constant and the
variation did not follow any specific trend as days progressed.
The change was probably due to the surrounding envi-
ronment on that specific day and time when the samples
were being analyzed for moisture content determination.
Thus variation was observed in the moisture content but did
not follow any trend with progression of the days. Figure 11
indicates the comparison of moisture content in samples at
different conditions of A, B, and C (Table 5).
3.3. Near Infrared Absorption Spectra. From the absorption
spectra (omeprazole Mg alone, omeprazole Mg: sodium
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Table 3: Micromeritics properties of omeprazole magnesium.
Sample Bulk density Tapped density Carr’s index Hauser’s ratio
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Figure 5: Absorption NIR spectra of omeprazole magnesium with
lactose.
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Figure 9: Absorption NIR spectra for omeprazole Mg with aerosil
200.
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Figure 10: AbsorptionNIR spectra for omeprazolemagnesiumwith
all potential excipients.
lauryl sulphate, omeprazole Mg: lactose, omeprazole Mg:
Avicel PH 101, omeprazole Mg: starch, and omeprazole Mg:
magnesium stearate) shown in Figures 3, 4, 5, 6, 7, 8, and 9,
respectively, it can be observed that the spectra overlap each
other and the peaks and troughs fall together with the refer-
ence spectra at different wavelengths of samples subjected to
all three conditions throughout the 90-day period. There is
no significant change in the nature of the absorption patterns
and the minor changes observed in the spectra are a result of
moisture variation in the samples.
By visual inspection of the spectra there is no significant
change in the spectra fromwavelength of 350–2500 nmwhich
includes the visible region (350–700 nm) and near infrared
region (800–2500 nm) but the important near infrared ranges
from 1100 to 2500 nm as strong bands (1100–2500 nm) are
related to overtone and combinations of fundamental vibra-
tions of OH, NH, and CH which are present in omeprazole
molecules.
The reference spectra at day zero were within and in
between the other spectra showing there was no change in
omeprazoleMg alone andwith the excipients when subjected
to different conditions for a period of 90 days.
There was no appearance change or colour change
observed in these samples fromday 0 to day 90 and all of them
remained white thoroughly and it is verified from the spectra
that there was no nature of change in absorption spectra even
in the visible region from 350 to 800 nm; thus no colour
change was observed in the samples.
From the absorption spectra of omeprazole magnesium
with aerosil 200, that is, Figure 10, there is a change in the
nature and absorption of spectra from 350 to 1000 nm which
was mainly the visible region of the spectrum; hence colour
change is observed in the samples as it is shown in the results
of appearance.
The spectra of sample kept in the climatic chamber have
deviatedmost in terms of absorption fromday zero (reference
spectrum) and that is why most of the colour change was
observed in these samples, that is, white > dark purple > dark
brown during the 90-day period.
The colour change was also observed in the sample kept
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Figure 11: Comparison of moisture content in samples at different
conditions A, B, and C.
brown and this is verified by the change of absorption spectra
in the visible region during the 90-day period.
Colour change was observed even in samples kept under
room temperature from white > dark purple > purple and
can be followed with the changes observed in the absorption
spectra in the visible region.
For the sample kept in the climatic chamber and oven,
there is a change in nature of spectra observed at wavelength
of about 500–550 nm; these could be due to heating of the
samples, that is, 40∘C in climatic chamber and 50∘C in oven.
This change of nature was not observed in samples kept in
the room temperature. The change is due to heating in both
climatic chamber and oven.
Colour changeswere observed in the samples subjected to
all three conditions corresponding to changes in the absorp-
tion spectra in the visible region; however no major changes
were observed in the important near infrared region (1100–
2500 nm). The colour of the samples was changing, that is,
physical changes, but there is no change in omeprazole struc-
ture as it can be observed that the spectra overlap each other
and the peaks and troughs fall together in the important near
infrared region throughout the 90-day period. The colour
change was due to the reaction between magnesium and
aerosil 200.
The absorption spectra for mixture of omeprazole mag-
nesium with all potential excipients were used for the com-
patibility studies; changes in absorption spectra were seen
only in the visible region (350–800 nm) in all three different
conditions which also led to the change of colour in the
samples as days progressed from day 0 to day 90 and this
colour change is due to aerosil 200 excipient which reacted
with magnesium part of omeprazole magnesium to form
magnesium silicide which is purple in colour.
The absorption spectra in the near infrared region overlap
each other and the peaks and troughs fall together. The refer-
ence spectrum (day 0 spectrum) was found in between other
spectra in the near infrared region. This shows that there
is no interaction between omeprazole and excipients. This
shows that aerosil 200 is incompatible with omeprazole mag-
nesium and should be avoided in the formulation phase.
3.4. Assay. Theassay results inTable 6 showed that therewere
no significant changes in the concentration of omeprazole
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Table 6: HPLC assay results for conditions A, B, and C.
Sampled days Omeprazole alone Omeprazole: all excipients
Condition: A—room, uncontrolled conditions—30 ± 2∘C
Day 0 100 100
Day 7 99.97 99.11
Day 30 99.48 98.93
Day 60 99.23 98.52
Day 90 99.14 98.26
Condition: B—room, controlled conditions—40 ± 2∘C/75% ± 5%RH
Day 0 100 100
Day 7 98.65 98.23
Day 30 97.40 97.60
Day 60 97.24 97.37
Day 90 96.94 96.95
Condition: C—oven (50∘C)
Day 0 100 100
Day 7 97.73 98.39
Day 30 97.10 97.85
Day 60 96.98 97.01
Day 90 96.75 96.68
magnesium from day 0 to day 90 and this indicates that
omeprazole magnesium is stable when subjected to condi-
tions of different temperature and humidity. Therefore the
selected excipient can be used to formulate stable omeprazole
tablets. This also indicates that omeprazole is compatible
when mixed with all selected excipients as the concentration
of omeprazole did not change significantly from day 0 to day
90.
4. Conclusion
The physical characteristics of omeprazole magnesium com-
ply with US Pharmacopeia standards with regard to the fair
flowability and fineness. From the above physical characteris-
tics of omeprazole magnesium, suitable excipients with their
respective amounts can be selected for the full formulation
of omeprazole enteric coated tablets. Even the formulation
method direct compression can be selected considering the
physical characteristics of omeprazole magnesium and the
excipients used.
The potential excipients, that is, sodium lauryl sulphate,
lactose, Avicel PH 101, starch, water aerosil 200, and mag-
nesium stearate, used in this study for compatibility with
omeprazolemagnesiumwere all compatible with omeprazole
magnesium powder when subjected to different conditions.
However water aerosil 200 which was mixed with omep-
razole magnesium showed physical changes, that is, colour
changes, when subjected to all conditions showing some
incompatibility with omeprazolemagnesiumpowder. Omep-
razole magnesium powder did not change when subjected
to stressful conditions of higher temperatures and relative
humidity.
There was no specific trend shown in moisture variation
as the number of days increases and the changes were due
to environment to which it was exposed; this was causing
absorption changes in near infrared spectra and thus some
spectra deviating from the reference spectra.
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